Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Condition(s):Mantle Cell LymphomaLast Updated:August 23, 2018Terminated
Hide Studies Not Open or Pending
Condition(s):Mantle Cell LymphomaLast Updated:August 23, 2018Terminated
Condition(s):Mantle Cell LymphomaLast Updated:January 28, 2022Completed
Condition(s):Mantle Cell Lymphoma (MCL)Last Updated:March 15, 2024Active, not recruiting
Condition(s):Follicular Lymphoma; Mantle Cell LymphomaLast Updated:September 27, 2021Terminated
Condition(s):Relapsed/Refractory Mantle Cell LymphomaLast Updated:April 24, 2020Completed
Condition(s):Lymphoma; Mantle Cell LymphomaLast Updated:January 23, 2024Recruiting
Condition(s):Mantle Cell Lymphoma; Ketogenic DietingLast Updated:August 28, 2023Withdrawn
Condition(s):Mantle Cell LymphomaLast Updated:May 9, 2023Active, not recruiting
Condition(s):Mantle Cell Lymphoma; Non-Hodgkin LymphomaLast Updated:January 11, 2024Active, not recruiting
Condition(s):Follicular Lymphoma; Marginal Zone Lymphoma; Mantle Cell LymphomaLast Updated:September 1, 2020Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.